A Myriad Conversation with Pandora Genomics

IPO Law Journal
August 2013

Partner Josh Rothman discussed the recent Myriad Supreme Court decision with President and Chief Scientific Officer of Pandora Genomics, Phil Arlen, Ph.D., in an article posted by the Intellectual Property Owners Association on August 22, 2013. The Supreme Court held that naturally occurring DNA is not patent eligible while non-naturally occurring DNA, and methods or processes of using naturally occurring DNA, are patent eligible. Dr. Arlen explains how he thinks the Myriad ruling may affect the biotech industry.

View Attachment (PDF)